David Shaywitz
banner
dshaywitz.bsky.social
David Shaywitz
@dshaywitz.bsky.social
Biology-grounded MD/PhD exec | Healthy aging & flourishing at scale | Evidence-based medicine x lifestyle × tech | Agency as engine of change | Strategic Advisor | Writer | kindwellhealth.com
Although i'm not sure this is quite right either, as I'd think may of the already healthy people would still see a provider for a check-up & perhaps preventive care. Zero claims (vs total claim value far below average) seems like it could reasonably be interpreted as signal folks not using system
November 11, 2025 at 4:21 PM
most of the debate right now seems to focus on accurately assessing the level...
November 11, 2025 at 3:35 PM
November 11, 2025 at 2:41 PM
100% which is why I also shared the @statnews.com piece, as it's more credible. Tricky with lots of gov health stuff b/c reflexively rejecting everything is going to miss true signal occaasionally...
November 11, 2025 at 2:14 PM
Hi - I'm not an expert on this subject and wouldn't pretend to offer medical advice on this deeply personal topic - but below is the reason offered by @openevidence.bsky.social for the change...
November 11, 2025 at 1:52 PM
Note this is actual eg shared with me this morning by person I encountered who turns out to sell insurance to those in this market-wanted to know if I knew what was going to happen w subsidies, his customers (mostly service workers I think) obviously concerned. @ashishkjha.bsky.social
November 11, 2025 at 12:08 PM
But question on table was deal a vs deal b…
November 10, 2025 at 7:20 PM
(ie Novo offer may have had higher headline number but was associated with less certainty for multiple reasons as I understand it)
November 10, 2025 at 5:13 PM
not if you believe as many seem to that counter offer was objectively worse, and not for jingoistic reasons...
November 10, 2025 at 5:12 PM
as always, i look forward to your assessment and insights!
November 10, 2025 at 2:07 PM
In contrast-was speaking w top VC (at another Chatham House rules event at Harvard) whose firm has invested in tech and biotech. The return in one area has gone through the roof. (hint: not biotech). The investor's point: you look at this dichotomy & ofc influences allocation... @gilman.bsky.social
November 9, 2025 at 8:40 PM
This is potentially relevant info - following the money at a16z - may offer useful perspective on associated media blitz -> www.fastcompany.com/91413783/and... (at end of day, not that complicated: pursuing bigger bets w bigger funds -> huge return from mgmt fees (plus: so far bets doing v well).
Here’s what Andreessen Horowitz's leaked decks mean for the future of venture capital
Investing’s megafunds have done well by catering to their limited partners. That opens up an opportunity for smaller funds.
www.fastcompany.com
November 9, 2025 at 8:36 PM
While there are an infinite number of communication platforms, there's also a mad competition to have one's voice heard above the din, and I understand completely while a16z - founded with a distinct vision for PR - now seeks to own/drive key communication, increasingly it seems w volume.
November 9, 2025 at 8:03 PM
My sense is in the absence of a single source of information, or a handful, it's now largely a free for all, everyone turns to their own sources for news and info, influencers have outsized power unfortunately, and seeking to dominate news/info flow in specific areas is rational - just irritating.
November 9, 2025 at 8:01 PM
Fun share, Eric! Not only interesting (& reassuring to many), but also part of the process of science-&, as the saying goes, why we do the experiment.
Here's a slide to this point I often include on talks on innovation and digital health - includes several prominent/classic egs from cardiology...
November 9, 2025 at 3:40 PM
Beware the Omnicause?
November 8, 2025 at 1:23 PM